Compounds > 1-(2-(4-aminophenyl)ethyl)-4-(3-trifluoromethylphenyl)piperazine
Page last updated: 2024-09-03

1-(2-(4-aminophenyl)ethyl)-4-(3-trifluoromethylphenyl)piperazine and Cardiac Failure

1-(2-(4-aminophenyl)ethyl)-4-(3-trifluoromethylphenyl)piperazine has been researched along with Cardiac Failure in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Adamson, PB; Bilchick, KC; Elumogo, C; Ginn, G; Hossack, JA; Jeukeng, C; Kennedy, JLW; Kwon, Y; Laja, O; Mazimba, S; Mehta, N; Mihalek, A; Mwansa, H; Pamboukian, SV; Parker, AM; Patterson, B; Sodhi, N; Tallaj, J1

Other Studies

1 other study(ies) available for 1-(2-(4-aminophenyl)ethyl)-4-(3-trifluoromethylphenyl)piperazine and Cardiac Failure

ArticleYear
Pulmonary Artery Proportional Pulse Pressure (PAPP) Index Identifies Patients With Improved Survival From the CardioMEMS Implantable Pulmonary Artery Pressure Monitor.
    Heart, lung & circulation, 2021, Volume: 30, Issue:9

    Topics: Blood Pressure; Heart Failure; Humans; Piperazines; Prognosis; Pulmonary Artery; Stroke Volume

2021